Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspirin Tops Three Rx Drugs In Preventing Heart Attack – Consumers Union

This article was originally published in The Tan Sheet

Executive Summary

Aspirin is the blood thinning agent of choice over three prescription antiplatelet medications for preventing first or repeat heart attack or stroke, according to a Consumers Union report

You may also be interested in...



Bayer Seeks To Reinvigorate Aspirin’s Pain Relief Profile

Bayer HealthCare recently launched its “Fast Relief Challenge” campaign to remind consumers about aspirin’s pain relief indication and to highlight Bayer Advanced Aspirin. The firm refers to a survey showing 8% of respondents preferred aspirin more than other OTC pain relievers.

Bayer Seeks To Reinvigorate Aspirin’s Pain Relief Profile

Bayer HealthCare recently launched its “Fast Relief Challenge” campaign to remind consumers about aspirin’s pain relief indication and to highlight Bayer Advanced Aspirin. The firm refers to a survey showing 8% of respondents preferred aspirin more than other OTC pain relievers.

Study reports benefits of aspirin plus Plavix

A study shows patients with atrial fibrillation reduced their risk of major vascular events by 11 percent by taking Plavix (clopidogrel) plus aspirin compared to aspirin alone. The results "suggest a potential change in clinical practice," says a study investigator. Findings announced March 31 from the ACTIVE A (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Cardiovascular Events) phase III double-blind, placebo-controlled trial also said the heart arrhythmia patients taking the antiplatelet drug and aspirin saw a 28 percent reduction in stroke during the median 3.6 years of follow-up. Bristol-Myers Squibb and Sanofi-Aventis, which jointly market Plavix, sponsored the study. Atrial fibrillation patients have a five-fold greater stroke risk and cannot take oral anticoagulants, a researcher said. A 2007 analysis found aspirin alone is more effective than Plavix and other Rx antiplatelets in preventing first or repeat heart attack or stroke (1"The Tan Sheet" April 23, 2007, p. 10)

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel